Lisanti Capital Growth’s OptimizeRx OPRX Stock Holding History

Lisanti Capital Growth’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-180,666	Closed	-$4.95M	–	129
2022 Q2	$4.95M	Buy	180,666 +101,075	+127%	+$3M	0.67%	66
2022 Q1	$3M	Sell	79,591 -7,830	-9%	-$347K	0.34%	99
2021 Q4	$5.43M	Sell	87,421 -14,185	-14%	-$1.07M	0.79%	55
2021 Q3	$8.69M	Sell	101,606 -745	-0.7%	-$46.7K	1.28%	20
2021 Q2	$6.34M	Buy	+102,351	New	+$5.21M	0.78%	52

Other funds holding OPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

GIPM

G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Lisanti Capital Growth's OPRX Position: Q3 2022 in Review

Lisanti Capital Growth sold out of OptimizeRx (OPRX) in Q3 2022, closing a stake of 180,666 shares — an estimated $4.95M sold.

Lisanti Capital Growth first reported a position in OPRX in Q2 2021 and held it in 5 quarters. The position peaked at $8.69M in Q3 2021. 128 funds tracked by Wall St. Rank hold OPRX as of Q3 2022.

Lisanti Capital Growth reported no remaining OptimizeRx position as of Q3 2022 after selling out during the quarter.
Lisanti Capital Growth sold 180,666 OptimizeRx shares in Q3 2022, an estimated $4.95M.
Lisanti Capital Growth first reported a position in OptimizeRx in Q2 2021 and held it in 5 quarters.
Lisanti Capital Growth's OptimizeRx position peaked at $8.69M in Q3 2021.
128 funds tracked by Wall St. Rank held OptimizeRx as of Q3 2022.

Based on Lisanti Capital Growth's 13F filing for Q3 2022, filed 2 Nov 2022.